Quaglino P, Fierro M T, Rossotto G L, Savoia P, Bernengo M G
Department of Medical Sciences and Human Oncology, Section of Dermatology, University of Turin, Turin, Italy.
Br J Dermatol. 2004 Feb;150(2):327-36. doi: 10.1111/j.1365-2133.2004.05712.x.
Purine analogues [fludarabine monophosphate (FAMP); deoxycoformycin and 2-chlorodeoxyadenosine) and extracorporeal photochemotherapy (ECP) have been suggested to be active agents in advanced cutaneous T-cell lymphoma (CTCL) patients.
To explore further the clinical efficacy and safety of FAMP monochemotherapy in advanced CTCL and to evaluate if the sequential association of ECP to FAMP in selected patients may improve the response rate (RR) and/or lengthen the remission duration.
Forty-four CTCL patients [17 Sézary syndrome (SS); 26 mycosis fungoides (MF), stage IIB-IV or with peripheral blood involvement; one MF associated with lymphomatoid papulosis (LyP)] were enrolled in this pilot cohort study. All the patients received FAMP 25 mg m(-2) 5 days monthly; 19 patients (43.2%) underwent ECP after FAMP was discontinued. The majority of patients with erythrodermic CTCL or peripheral blood involvement underwent the combined FAMP-ECP schedule.
After a median follow-up of 4.2 years, the overall FAMP RR was 29.5% (13/44); a higher RR was obtained in SS (35.3%) than in MF patients (25.9%). According to the treatment group, the RR of the FAMP-ECP group (63.2%) was significantly higher than that of the FAMP monotherapy group (24%; P=0.021). No statistically significant difference was found in time-to-progression (TTP) or survival by therapy group, even if the TTP of the patients treated with the FAMP-ECP combination therapy was higher (median 13 vs. 7 months). A decrease or a normalization in the CD4+CD26- circulating subset was observed in responding patients, paralleling the reduction in the circulating Sézary cells.
FAMP confirms its clinical activity as a single agent in SS; conversely, FAMP results do not compare favourably with other therapeutic approaches for advanced stage MF patients. The sequential association of ECP after FAMP seems to increase the RR, even if future randomized studies are needed to confirm these results.
嘌呤类似物[氟达拉滨单磷酸盐(FAMP);脱氧助间型霉素和2-氯脱氧腺苷]以及体外光化学疗法(ECP)被认为是晚期皮肤T细胞淋巴瘤(CTCL)患者的有效治疗药物。
进一步探究FAMP单药化疗在晚期CTCL中的临床疗效和安全性,并评估在部分患者中ECP与FAMP序贯联合使用是否可提高缓解率(RR)和/或延长缓解持续时间。
44例CTCL患者[17例塞扎里综合征(SS);26例蕈样肉芽肿(MF),IIB-IV期或有外周血受累;1例MF合并淋巴瘤样丘疹病(LyP)]纳入了这项前瞻性队列研究。所有患者每月5天接受25mg/m²的FAMP治疗;19例患者(43.2%)在停用FAMP后接受了ECP治疗。大多数红皮病型CTCL或外周血受累患者接受了FAMP-ECP联合治疗方案。
中位随访4.2年后,FAMP的总体RR为29.5%(13/44);SS患者的RR(35.3%)高于MF患者(25.9%)。根据治疗组,FAMP-ECP组的RR(63.2%)显著高于FAMP单药治疗组(24%;P=0.021)。治疗组之间在疾病进展时间(TTP)或生存率方面未发现统计学显著差异,尽管接受FAMP-ECP联合治疗的患者TTP更高(中位值13个月对7个月)。在有反应的患者中观察到CD4+CD26-循环亚群减少或恢复正常,这与循环塞扎里细胞的减少相平行。
FAMP证实其作为SS单药治疗具有临床活性;相反,对于晚期MF患者,FAMP的疗效不如其他治疗方法。FAMP后序贯联合ECP似乎可提高RR,尽管需要未来的随机研究来证实这些结果。